Abecma cuts worse outcomes risk in half in hard-to-treat myeloma cases
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma…
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma…